CERo Therapeutics (CEROW) Competitors $0.02 0.00 (-5.63%) As of 08/19/2025 02:49 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock CEROW vs. ATNFW, SXTPW, DRTSW, APLMW, BCTXW, CDIOW, CELUW, CINGW, CLNNW, and COEPWShould you be buying CERo Therapeutics stock or one of its competitors? The main competitors of CERo Therapeutics include 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Alpha Tau Medical (DRTSW), Apollomics (APLMW), BriaCell Therapeutics (BCTXW), Cardio Diagnostics (CDIOW), Celularity (CELUW), Cingulate (CINGW), Clene (CLNNW), and Coeptis Therapeutics (COEPW). These companies are all part of the "biotechnology" industry. CERo Therapeutics vs. Its Competitors 180 Life Sciences 60 Degrees Pharmaceuticals Alpha Tau Medical Apollomics BriaCell Therapeutics Cardio Diagnostics Celularity Cingulate Clene Coeptis Therapeutics CERo Therapeutics (NASDAQ:CEROW) and 180 Life Sciences (NASDAQ:ATNFW) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment. Which has higher valuation & earnings, CEROW or ATNFW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCERo TherapeuticsN/AN/AN/AN/AN/A180 Life SciencesN/AN/AN/AN/AN/A Does the media prefer CEROW or ATNFW? In the previous week, 180 Life Sciences had 1 more articles in the media than CERo Therapeutics. MarketBeat recorded 1 mentions for 180 Life Sciences and 0 mentions for CERo Therapeutics. 180 Life Sciences' average media sentiment score of 0.80 beat CERo Therapeutics' score of 0.00 indicating that 180 Life Sciences is being referred to more favorably in the news media. Company Overall Sentiment CERo Therapeutics Neutral 180 Life Sciences Positive Is CEROW or ATNFW more profitable? Company Net Margins Return on Equity Return on Assets CERo TherapeuticsN/A N/A N/A 180 Life Sciences N/A N/A N/A Summary180 Life Sciences beats CERo Therapeutics on 2 of the 2 factors compared between the two stocks. Get CERo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CEROW and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CEROW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CEROW vs. The Competition Export to ExcelMetricCERo TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$139.23M$5.73B$9.80BDividend YieldN/A3.74%4.54%4.09%P/E RatioN/A3.8830.7425.12Price / SalesN/A4,150.02417.1796.71Price / CashN/A13.1937.3459.16Price / BookN/A48.118.886.24Net IncomeN/A-$90.99M$3.26B$265.56M7 Day PerformanceN/A2.52%-0.40%-0.74%1 Month PerformanceN/A6.23%3.54%1.95%1 Year PerformanceN/A183.58%28.54%21.14% CERo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CEROWCERo TherapeuticsN/A$0.02-5.6%N/A-39.6%$0.00N/A0.008ATNFW180 Life SciencesN/A$0.46-16.3%N/A+4,370.6%$0.00N/A0.007Gap DownHigh Trading VolumeSXTPW60 Degrees PharmaceuticalsN/A$0.09-10.5%N/A+82.8%$0.00$665.45K0.002News CoverageGap UpDRTSWAlpha Tau MedicalN/A$0.27-1.1%N/A+47.4%$0.00N/A0.0080Gap UpAPLMWApollomicsN/A$0.02-8.8%N/A+135.0%$0.00N/A0.0059Positive NewsShort Interest ↓Gap UpBCTXWBriaCell TherapeuticsN/A$0.03-9.7%N/A-87.1%$0.00N/A0.008Negative NewsGap DownCDIOWCardio DiagnosticsN/A$0.01+0.7%N/A-68.7%$0.00$19.90K0.007Positive NewsShort Interest ↓Gap UpCELUWCelularityN/A$0.05+9.9%N/A+199.5%$0.00$54.22M0.00220CINGWCingulateN/A$0.06-4.7%N/A-62.0%$0.00N/A0.0020Positive NewsGap DownCLNNWCleneN/A$0.03-6.1%N/A-5.4%$0.00$350K0.00100Positive NewsGap DownCOEPWCoeptis TherapeuticsN/A$0.02-0.8%N/A+0.0%$0.00$62.87K0.004Positive News Related Companies and Tools Related Companies ATNFW Competitors SXTPW Competitors DRTSW Competitors APLMW Competitors BCTXW Competitors CDIOW Competitors CELUW Competitors CINGW Competitors CLNNW Competitors COEPW Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CEROW) was last updated on 8/20/2025 by MarketBeat.com Staff From Our PartnersWinning the AI WarWhat’s really driving the trade wars, reshoring, and sweeping executive orders? According to Porter Stansberry...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CERo Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CERo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access